BMI, fasting glucose, and intermediate and small HDL subfractions are found to be predictors of afamin in this study; therefore, afamin may serve as a potential biomarker for the severity of cardiometabolic disturbances, including impaired lipid and/or glucose metabolism in obesity. This evidence concerns the gene AFM and obesity disorder.